Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Hemostemix (HEM) Stock Price & Analysis

HEM Stock Chart & Stats

CA$0.06CA$0.00(0.00%)
At close: 9:59 AM EST
C$0.05C$0.06C$0.07C$0.0810 Aug24 Aug8 Sep21 Sep5 Oct19 Oct2 Nov
Day’s Range
CAD 0.05 - CAD 0.06
52-Week Range
CAD 0.04 - CAD 0.11
Previous Close
CAD 0.06
Volume
N/A
Average Volume (3M)
34.59K
Market Cap
CAD 11.63M
Enterprise Value
CAD 14.23M
Total Cash (Recent Filing)
CAD 196.46K
Total Debt (Recent Filing)
CAD 3.56M
Price to Earnings (P/E)
―
Beta
0.53
Next Earnings
Nov 27, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Regenerative Medicine Platform

Hemostemix is focused on a specialized regenerative-medicine platform rather than a broad, unfocused pipeline. Its patient-derived approach and emphasis on vascular regeneration provide a defined scientific strategy that could support differentiated clinical value if development succeeds.

Debt Has Declined From Peak

Debt not steadily increasing provides a limited measure of balance-sheet discipline and avoids adding a continuously rising obligation. This relative improvement may preserve some financing flexibility, although negative equity and the small asset base still materially constrain the benefit.

Cash Losses Reflect Operating Losses

Close alignment between free cash flow and net income suggests the reported losses are translating into visible cash consumption rather than being primarily driven by non-cash accounting items. That improves transparency around funding needs and supports clearer assessment of operating performance.

Bears Say

Pre-commercial Revenue Profile

The absence of revenue confirms that Hemostemix remains pre-commercial and has not yet demonstrated product-market monetization. Until a therapy reaches commercialization, the company cannot rely on operating revenue to fund development, making progress dependent on successful clinical and regulatory execution.

Stressed Balance Sheet

Negative equity combined with a very small asset base leaves limited financial resilience and makes leverage more concerning. This structure can restrict strategic flexibility and increase reliance on refinancing or new capital, creating ongoing dilution and funding risk during development.

Worsening Cash Burn

Persistent and worsening cash burn indicates that the company is consuming capital without internally generated funding to sustain operations. Continued negative free cash flow raises the likelihood of additional financing needs and could divert management attention toward liquidity rather than advancing the clinical program.

Hemostemix News

HEM FAQ

What was Hemostemix’s price range in the past 12 months?
Hemostemix lowest stock price was C$0.04 and its highest was C$0.11 in the past 12 months.
What is Hemostemix’s market cap?
Hemostemix’s market cap is C$11.63M.
When is Hemostemix’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Hemostemix’s earnings last quarter?
Hemostemix released its earnings results on Aug 31, 2026. The company reported -C$0.003 earnings per share for the quarter.
Is Hemostemix overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Hemostemix pay dividends?
Hemostemix does not currently pay dividends.
What is Hemostemix’s EPS estimate?
Hemostemix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hemostemix have?
Hemostemix has 211,441,440 shares outstanding.
What happened to Hemostemix’s price movement after its last earnings report?
Hemostemix reported an EPS of -C$0.003 in its last earnings report. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Hemostemix?
Currently, no hedge funds are holding shares in TSE:HEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology